Esomeprazole sodium (Synonyms:(S-Omeprazole sodium; (-)-Omeprazole sodium))
目录号 : KM12462 CAS No. : 161796-78-7 纯度 : 98%

Esomeprazole sodium ((S)-Omeprazole sodium) 是一种有效的具有口服活性质子泵 (proton pump) 抑制剂,可通过抑制胃壁细胞中的 H+, K+-ATPase 来降低酸分泌,并可用于胃食管反流疾病的研究。Esomeprazole 是一种外泌体抑制剂,通过抑制 V-H+-ATPases 来阻断外泌体的释放。

规格 价格 是否有货 数量
10mg
In-stock
50mg
In-stock
100mg
In-stock
250mg
In-stock
500mg 询价 In-stock
1g 询价 In-stock

Other Forms of Rapamycin:

KKL Med 的所有产品和服务仅用于科学研究,不能被用于人体,兽医,我们也不向个人提供产品和服务。
生物活性

Esomeprazole sodium ((S)-Omeprazole sodium) is a potent and orally active proton pump inhibitor. Esomeprazole reduces acid secretion through inhibition of the H, K-ATPase in gastric parietal cells. Esomeprazole acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H-ATPases. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research.

体外研究

Esomeprazole (25-100 µM; 20 hours; MDA-MB-468 cells) treatment suppresses growth of triple-negative breast cancer cell in vitro in a dose-dependent manner through increase in their intracellular acidification.

Cell Viability Assay

Cell Line: MDA-MB-468 cells
Concentration: 25 µM, 50 µM, 75 µM, 100 µM
Incubation Time: 20 hours
Result: Suppressed growth of triple-negative breast cancer cell in vitro in a dose-dependent manner.
体内研究

Esomeprazole (30-300 mg/kg; oral gavage; daily; for 19 or 11 days; C57BL/6J mice) treatment significantly inhibits the progression of fibrosis throughout the lungs of the animals. Esomeprazole also reduces circulating markers of inflammation and fibrosis.

Animal Model: C57BL/6J mice (8-weeks old, 25-30 g) treated with cotton smoke-induced lung injury
Dosage: 30 mg/kg, 300 mg/kg
Administration: Oral gavage; daily; for 19 or 11 days
Result: Significantly inhibited the progression of fibrosis throughout the lungs of the animals.
分子式
C17H19N3NaO3S
分子量
367.40
CAS号
161796-78-7
中文名称
埃索美拉唑钠盐
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture and light

*该产品在溶液状态不稳定,建议您现用现配,即刻使用。

溶解性数据
In Vitro: 

DMSO : 100 mg/mL (272.18 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.7218 mL 13.6091 mL 27.2183 mL
5 mM 0.5444 mL 2.7218 mL 5.4437 mL
10 mM 0.2722 mL 1.3609 mL 2.7218 mL
*

请根据产品在不同溶剂中的溶解度,选择合适的溶剂配制储备液;该产品在溶液状态不稳定,建议您现用现配,即刻使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (5.66 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (5.66 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (5.66 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (5.66 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (5.66 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (5.66 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

临床试验
The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
在线客服
咨询热线
400-881-9290
关注微信公众号